Co-Expression of Molecular Chaperones to Enhance Soluble aPD-L1 scFv Production in Escherichia coli BL21(DE3).
- 1Department of Biology, Faculty of Science, Chiang Mai University, Chiang Mai 50200, Thailand.
- 2Cell Engineering for Cancer Therapy Research Group, Chiang Mai University, Chiang Mai 50200, Thailand.
Abstract
Production of commercial antibodies commonly relies on mammalian expression platforms; however, these are associated with high production costs and technical challenges during large-scale cultivation. In this study, we aimed to develop an Escherichia coli-based platform for the production of an anti-PD-L1 single-chain variable fragment, hereafter aPD-L1 scFv. Expression of aPD-L1 scFv in E. coli BL21(DE3) resulted in extensive inclusion body formation regardless of the expression temperatures at 16 °C, 30 °C, and 37 °C, with approximately 84-93% accumulating in the insoluble fraction. To improve its solubility, co-expression with several molecular chaperones, namely DnaK-DnaJ-GrpE and GroES-GroEL, was investigated. Optimization of L-arabinose concentrations as an inducer for DnaK-DnaJ-GrpE expression demonstrated that induction at 0.15 mg/mL increased aPD-L1 scFv solubility from 5.13% to 23.97%, although the difference was not statistically significant. Moreover, His-tag purification yielded 14.78 µg/mL and 18.62 µg/mL without and with molecular chaperone co-expression, respectively. The binding activity of purified aPD-L1 scFv was confirmed by ELISA, which showed comparable binding signals following chaperone-assisted expression. This indicated that the functional activity was retained. Altogether, these findings suggest that molecular chaperone co-expression has the potential to increase the soluble production of functional aPD-L1 scFv in E. coli, supporting the feasibility of bacterial expression systems as a cost-effective platform for recombinant antibody fragment production.
Related
- Genetic Variants in HSP70 Family Genes and Their Co-Chaperones Are Associated with Ischemic Stroke Susceptibility and Gene Expression During Acute and Early Recovery Phases
- Iterative genome editing of Escherichia coli for 3-hydroxypropionic acid production
- Systems metabolic engineering of a plasmid-free Escherichia coli cell factory for high-level cytidine production
- Lactate promotes mitochondrial biogenesis and fusion via GPR81 to enhance synaptic plasticity-related protein expression in hippocampal cells
- Expression and Purification of Recombinant Duck Ovalbumin in Escherichia coli
BibTeX
@article{khamthiang2026coexpression,
title = {{Co-Expression of Molecular Chaperones to Enhance Soluble aPD-L1 scFv Production in Escherichia coli BL21(DE3).}},
author = {Sarinthip Khamthiang and Chonlaphon Juntama and Aussara Panya and Pachara Sattayawat},
journal = {Life (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/life16101664},
url = {https://europepmc.org/article/MED/42942250},
note = {CC BY},
}
RIS
TY - JOUR
TI - Co-Expression of Molecular Chaperones to Enhance Soluble aPD-L1 scFv Production in Escherichia coli BL21(DE3).
AU - Sarinthip Khamthiang
AU - Chonlaphon Juntama
AU - Aussara Panya
AU - Pachara Sattayawat
PY - 2026
DA - 2026/10/03
JO - Life (Basel, Switzerland)
DO - 10.3390/life16101664
UR - https://europepmc.org/article/MED/42942250
AB - Production of commercial antibodies commonly relies on mammalian expression platforms; however, these are associated with high production costs and technical challenges during large-scale cultivation. In this study, we aimed to develop an Escherichia coli-based platform for the production of an anti-PD-L1 single-chain variable fragment, hereafter aPD-L1 scFv. Expression of aPD-L1 scFv in E. coli BL21(DE3) resulted in extensive inclusion body formation regardless of the expression temperatures at 16 °C, 30 °C, and 37 °C, with approximately 84-93% accumulating in the insoluble fraction. To improve its solubility, co-expression with several molecular chaperones, namely DnaK-DnaJ-GrpE and GroES-GroEL, was investigated. Optimization of L-arabinose concentrations as an inducer for DnaK-DnaJ-GrpE expression demonstrated that induction at 0.15 mg/mL increased aPD-L1 scFv solubility from 5.13% to 23.97%, although the difference was not statistically significant. Moreover, His-tag purification yielded 14.78 µg/mL and 18.62 µg/mL without and with molecular chaperone co-expression, respectively. The binding activity of purified aPD-L1 scFv was confirmed by ELISA, which showed comparable binding signals following chaperone-assisted expression. This indicated that the functional activity was retained. Altogether, these findings suggest that molecular chaperone co-expression has the potential to increase the soluble production of functional aPD-L1 scFv in E. coli, supporting the feasibility of bacterial expression systems as a cost-effective platform for recombinant antibody fragment production.
SN - 2075-1729
ER -